Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
Jiawen Deng, Kiyan Heybati, Harikrishnaa Ba Ramaraju, et al.
Infection (2022) Vol. 51, Iss. 1, pp. 21-35
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Effectiveness of pharmacological treatments for COVID-19 due to SARS-CoV-2: a systematic literature review
Carolina García‐Vidal, Júlia de Oliveira Gonzalez, Carlos Lumbreras, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation
Hung Van Nguyen, Hoang Linh Nguyen, Pham Dang Lan, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 18, pp. 6497-6553
Closed Access | Times Cited: 9
Evaluating fluvoxamine for the outpatient treatment of COVID‐19: A systematic review and meta‐analysis
Jiawen Deng, Myron Moskalyk, Qi Zuo, et al.
Reviews in Medical Virology (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 9
Clinical efficacy and safety of SARS-CoV-2-neutralizing monoclonal antibody in patients with COVID-19: A living systematic review and meta-analysis
Su‐Yeon Yu, Miyoung Choi, Chelim Cheong, et al.
Journal of Microbiology Immunology and Infection (2023) Vol. 56, Iss. 5, pp. 909-920
Open Access | Times Cited: 8
CLINICAL EFFECTIVENESS OF CASIRIVIMAB AND IMDEVIMAB COMPARED WITH STANDARD OF CARE IN COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
Amirhossein Orandi, Mojhgan Mohajeri, Mohsen Mansouri, et al.
Studies in Medical Sciences (2024) Vol. 34, Iss. 11, pp. 727-741
Open Access | Times Cited: 2
Interventions to Improve Adherence to Oral Pre-exposure Prophylaxis: A Systematic Review and Network Meta-analysis
Cristian Garcia, Nadia Rehman, Jéssyca Matos-Silva, et al.
AIDS and Behavior (2024) Vol. 28, Iss. 8, pp. 2534-2546
Closed Access | Times Cited: 2
Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic
Giulia Garzi, Francesco Cinetto, Davide Firinu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Efficacy of tocilizumab in the treatment of COVID‐19: An umbrella review
Mohammad Mahdi Rezaei Tolzali, Maryam Noori, Pourya Shokri, et al.
Reviews in Medical Virology (2022) Vol. 32, Iss. 6
Open Access | Times Cited: 11
Therapeutic antibodies and alternative formats against SARS-CoV-2
Rahel R. Winiger, Laurent Perez
Antiviral Research (2024) Vol. 223, pp. 105820-105820
Open Access | Times Cited: 1
Analysis of how antigen mutations disrupt antibody binding interactions toward enabling rapid and reliable antibody repurposing
Sumaiya Islam, Varun M. Chauhan, Robert J. Pantazes
mAbs (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 1
COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance
Sabine Bou-Antoun, Sakib Rokadiya, Diane Ashiru‐Oredope, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. Supplement_2, pp. ii37-ii42
Open Access | Times Cited: 4
Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
Junzheng Wu, Huichuan Yang, Ding Yu, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 3
Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy
Manlio Mencoboni, Vincenzo Fontana, Azzurra Damiani, et al.
Current Oncology (2022) Vol. 29, Iss. 5, pp. 3364-3374
Open Access | Times Cited: 5
Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19
Jingrui Zou, Fuyuan Jing
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1472-1472
Open Access | Times Cited: 5
Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK
Amanda Goodwin, Jonathan Thompson, Ian P. Hall
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0281915-e0281915
Open Access | Times Cited: 2
Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: A systematic review and meta-analysis randomized controlled trial
Imam Adi Wicaksono, Cecep Suhandi, Khaled M. Elamin, et al.
Heliyon (2023) Vol. 9, Iss. 12, pp. e22839-e22839
Open Access | Times Cited: 2
Would New SARS-CoV-2 Variants Change the War against COVID-19?
Elrashdy M. Redwan, Fatma Elrashdy, Alaa A. A. Aljabali, et al.
Epidemiologia (2022) Vol. 3, Iss. 2, pp. 229-237
Open Access | Times Cited: 4
Pharmacological prevention of bone loss and fractures following solid organ transplantations: Protocol for a systematic review and network meta-analysis
Jiawen Deng, Myron Moskalyk, Wenteng Hou, et al.
PLoS ONE (2024) Vol. 19, Iss. 4, pp. e0302566-e0302566
Open Access
Efficacy and safety of casirivimab and imdevimab for preventing and treating COVID-19: a systematic review and meta-analysis
Zhifang Cui, Hongwu Wang, Heng Zou, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 6, pp. 3606-3622
Open Access
Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials
Ana Flávia Amorim, Joselin Valeska Martinez-Sobalvarro, Larissa Helena Torres, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 12, pp. 9573-9589
Closed Access
Evaluating Personalized Add-On Ayurveda Therapy in Oxygen-Dependent Diabetic COVID-19 Patients: A 60-Day Study of Symptoms, Inflammation, and Radiological Changes
Somit Kumar, Karthikeyan Ramaraju, Mitravinda Sai Kakarla, et al.
Cureus (2024)
Open Access
COMPARING THE EFFECTIVENESS AND SAFETY OF CASIRIVIMAB/IMDEVIMAB WITH BAMLANIVIMAB IN PATIENTS WITH COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
Maryam Karimi Babaahmadi, Mojhgan Mohajeri Iravani, Amirhossein Orandi, et al.
Studies in Medical Sciences (2024) Vol. 35, Iss. 4, pp. 250-264
Closed Access
Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge
Claudia Bartalucci, Alessandro Limongelli, Laura Ambra Nicolini, et al.
Journal of Chemotherapy (2023) Vol. 36, Iss. 4, pp. 283-290
Closed Access | Times Cited: 1
Medications for early treatment of COVID ‐19 in Australia
Adam Polkinghorne, James Branley
The Medical Journal of Australia (2022) Vol. 217, Iss. S9
Open Access | Times Cited: 2
Targeting patients for early COVID-19 therapy; Pre-infection metabolic dysfunction, polycystic ovary syndrome and risk of severe disease in patients under 65: A Massachusetts community-based observational study
Susan Sama, Rebecca Gore, Ann Z. Bauer, et al.
PLoS ONE (2023) Vol. 18, Iss. 6, pp. e0287430-e0287430
Open Access
Page 1 - Next Page

Scroll to top